Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Aclaris Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Aclaris Therapeutics, Inc.’s stock price such as:

• Aclaris Therapeutics, Inc.’s current stock price and volume
• Why Aclaris Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for ACRS from analysts
• ACRS’s stock price momentum as measured by its relative strength

About Aclaris Therapeutics, Inc. (ACRS)

Before we jump into Aclaris Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatment of atopic dermatitis and other dermatologic conditions; Bosakitug (ATI-045), an anti-TSLP monoclonal antibody in Phase 2a trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; Zunsemetinib (ATI-450), a mitogen-activated protein kinase-activated protein kinase 2 inhibitor under Phase 1b/2 trials for the treatment of metastatic breast cancer and pancreatic ductal adenocarcinoma; and ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in preclinical stage to treat various atopic, immunologic, and respiratory diseases, as well as an ITK selective inhibitor candidate for the treatment of autoimmune diseases. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Want to learn more about Aclaris Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Aclaris Therapeutics, Inc..

Aclaris Therapeutics, Inc.’s Stock Price as of Market Close

As of June 11, 2025, 1:15 PM, CST, Aclaris Therapeutics, Inc.’s stock price was $1.565.

Aclaris Therapeutics, Inc. is up 3.64% from its previous closing price of $1.510.

During the last market session, Aclaris Therapeutics, Inc.’s stock traded between $1.484 and $1.580. Currently, there are approximately 122.39 million shares outstanding for Aclaris Therapeutics, Inc..

Aclaris Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Aclaris Therapeutics, Inc. Stock Price History

Aclaris Therapeutics, Inc.’s (ACRS) price is currently up 7.19% so far this month.

During the month of June, Aclaris Therapeutics, Inc.’s stock price has reached a high of $1.650 and a low of $1.420.

Over the last year, Aclaris Therapeutics, Inc. has hit prices as high as $5.170 and as low as $1.010. Year to date, Aclaris Therapeutics, Inc.’s stock is down 36.9%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Aclaris Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 10, 2025, there was 1 analyst who downgraded Aclaris Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Aclaris Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Aclaris Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Aclaris Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Aclaris Therapeutics, Inc. (ACRS) by visiting AAII Stock Evaluator.

Relative Price Strength of Aclaris Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 10, 2025, Aclaris Therapeutics, Inc. has a weighted four-quarter relative price strength of 26.87%, which translates to a Momentum Score of 95 and is considered to be Very Strong.

Want to learn more about how Aclaris Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Aclaris Therapeutics, Inc. Stock Price: Bottom Line

As of June 11, 2025, Aclaris Therapeutics, Inc.’s stock price is $1.565, which is up 3.64% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Aclaris Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.